Zimmer Biomet Holdings (1ZBH) Stock Overview
Operates as a medical technology company worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 4/6 |
1ZBH Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Zimmer Biomet Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$87.22 |
| 52 Week High | US$94.94 |
| 52 Week Low | US$88.00 |
| Beta | 0.67 |
| 1 Month Change | 4.63% |
| 3 Month Change | 9.79% |
| 1 Year Change | n/a |
| 3 Year Change | -17.23% |
| 5 Year Change | -27.32% |
| Change since IPO | -33.42% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1ZBH | IT Medical Equipment | IT Market | |
|---|---|---|---|
| 7D | -1.0% | -2.3% | 1.4% |
| 1Y | n/a | -19.4% | 24.3% |
Return vs Industry: Insufficient data to determine how 1ZBH performed against the Italian Medical Equipment industry.
Return vs Market: Insufficient data to determine how 1ZBH performed against the Italian Market.
Price Volatility
| 1ZBH volatility | |
|---|---|
| 1ZBH Average Weekly Movement | 4.2% |
| Medical Equipment Industry Average Movement | 4.0% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in IT Market | 7.7% |
| 10% least volatile stocks in IT Market | 2.3% |
Stable Share Price: 1ZBH has not had significant price volatility in the past 3 months compared to the Italian market.
Volatility Over Time: 1ZBH's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1927 | 17,000 | Ivan Tornos | www.zimmerbiomet.com |
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It offers technology and data, bone cement, and surgical products.
Zimmer Biomet Holdings, Inc. Fundamentals Summary
| 1ZBH fundamental statistics | |
|---|---|
| Market cap | €17.28b |
| Earnings (TTM) | €714.39m |
| Revenue (TTM) | €6.80b |
Is 1ZBH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1ZBH income statement (TTM) | |
|---|---|
| Revenue | US$7.83b |
| Cost of Revenue | US$2.25b |
| Gross Profit | US$5.58b |
| Other Expenses | US$4.76b |
| Earnings | US$823.50m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Nov 05, 2025
| Earnings per share (EPS) | 4.16 |
| Gross Margin | 71.25% |
| Net Profit Margin | 10.51% |
| Debt/Equity Ratio | 61.6% |
How did 1ZBH perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/02 09:03 |
| End of Day Share Price | 2025/10/31 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Zimmer Biomet Holdings, Inc. is covered by 48 analysts. 26 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Jeffrey Johnson | Baird |
| Adam Feinstein | Barclays |